Insider Transactions in Q3 2023 at Fibrogen Inc (FGEN)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 22
2023
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
819
-0.27%
|
$0
$0.79 P/Share
|
|
Sep 07
2023
|
Juan Graham CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,096
-0.58%
|
$0
$0.99 P/Share
|
|
Sep 06
2023
|
Mark Eisner EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,860
-1.15%
|
$0
$0.96 P/Share
|
|
Sep 06
2023
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,680
-0.55%
|
$0
$0.96 P/Share
|
|
Sep 06
2023
|
Juan Graham CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
711
-0.37%
|
$0
$0.96 P/Share
|
|
Sep 06
2023
|
Christine Chung SVP, CHINA OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
3,308
-0.93%
|
$0
$0.96 P/Share
|
|
Sep 01
2023
|
Jeffrey William Henderson Director |
SELL
Open market or private sale
|
Direct |
2,000
-6.48%
|
$2,000
$1.03 P/Share
|
|
Sep 01
2023
|
Mark Eisner EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,085
-0.67%
|
$1,085
$1.06 P/Share
|
|
Aug 30
2023
|
Christine Chung SVP, CHINA OPERATIONS |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+25.19%
|
-
|
|
Aug 30
2023
|
Juan Graham CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+38.57%
|
-
|
|
Aug 07
2023
|
Thane Wettig CEO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+39.35%
|
-
|
|
Aug 04
2023
|
Jeffrey William Henderson Director |
SELL
Open market or private sale
|
Direct |
2,000
-6.09%
|
$2,000
$1.91 P/Share
|
|
Jul 11
2023
|
Jeffrey William Henderson Director |
SELL
Open market or private sale
|
Direct |
2,000
-5.74%
|
$4,000
$2.69 P/Share
|
|
Jul 07
2023
|
Enrique A Conterno Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,880
-0.5%
|
$3,760
$2.8 P/Share
|